评估使用类似葡萄糖-1受体激动剂对自身免疫性疾病风险的因果关系
Yuming Sun1, Qian Zhou2, Lorraine Edna Onzere3
1Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China; Furong Laboratory, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Diabetes & metabolic syndrome
|January 10, 2025
概括
葡萄糖类-1受体 (GLP1R) 激动剂与几种自身免疫性疾病有关,可能影响甲状腺功能低下,性结肠炎,1型糖尿病,狼和沙尔科伊多सिस. 这些影响可能源于免疫细胞表型的改变.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 遗传学 遗传学 是一个
背景情况:
- 葡萄糖类-1受体 (GLP1R) 激动剂越来越多地用于2型糖尿病.
- GLP1R激动剂对自身免疫性疾病的潜在影响尚不清楚.
- 了解这些关联对于患者安全和治疗指导至关重要.
研究的目的:
- 研究GLP1R激动剂的使用与患各种自身免疫性疾病的风险之间的因果关系.
- 通过检查GLP1R激动剂对免疫细胞表型的影响来探索这些关联的潜在机制.
主要方法:
- 用于GLP1R的cis-eQTL作为GLP1R激动剂暴露的遗传代理.
- 采用孟德尔随机化 (MR) 来评估与11种自身免疫性疾病的关联,使用2型糖尿病作为阳性对照.
- 复制了FinnGen研究中的发现,并进行了元分析. 对731种免疫细胞表型进行了进一步的MR分析.
主要成果:
- GLP1R激动剂与降低甲状腺功能低下的风险 (OR=0.89) 相关,但增加了性结肠炎 (OR=1.48),1型糖尿病 (OR=1.34),全身性红斑狼 (OR=1.61) 和肉类症 (OR=1.38) 的风险.
- 对于喘,克罗恩病,多发性硬化症或肌痛性硬化症没有发现显著的关联.
- GLP1R激动剂与221个正相关和317个负相关的免疫细胞表型有显著的关联.
结论:
- GLP1R激动剂与几种自身免疫性疾病存在因果关系.
- 观察到的关联可以通过调节广泛的免疫细胞表型来调节.
- 这些发现强调了代谢药物和免疫系统调节之间的复杂相互作用.
相关概念视频
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Autoimmune Disorders
385
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
385
Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
GPCRs Regulate Adenylyl Cylase Activity
5.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.3K


